Longevity Biosplice files FDA application for knee osteoarthritis drugBy adminJanuary 15, 20260 Biosplice submits NDA for lorecivivint, a potential first-of-its-kind therapy that aims to slow knee osteoarthritis itself. Osteoarthritis shapes how millions…